State role
The BHA may operate the state licensing component for up to five pilot sites and support coordination around the pilot’s research framework, screening, monitoring, and benefit-sharing requirements.
COLORADO / POLICY NOTE
Policy Snapshot
Colorado HB 26-1325 creates a limited Ibogaine Research Pilot Program. It authorizes a state-administered research framework; it does not make ibogaine generally legal, available by prescription under state law, or available for retail sale.
A narrow state pilot, inside a still-federal regulatory system.
01 / THE LANE
What HB 26-1325 authorizes
HB 26-1325 establishes Colorado’s Ibogaine Research Pilot Program. The framework directs the Behavioral Health Administration (BHA) to license up to five pilot sites and gives the state a defined role in supporting coordination with federal agencies. For orientation beyond the state program, our Colorado policy landscape overview separates this pilot from broader claims about availability.
The bill’s text sets out a research-focused model rather than a consumer market. It includes required participant screening, monitoring, and benefit-sharing provisions. Those safeguards are part of the structure contemplated by the Colorado General Assembly’s HB 26-1325 record; they do not turn the pilot into general medical access.
The practical question is therefore not whether a new storefront category exists. It is whether a federally workable research pathway can be assembled within the state framework. People comparing terminology used outside Colorado may encounter an ibogaine street-name glossary, but informal language does not describe the legal status of a controlled substance or the limits of this program.
02 / THE EDGE
What the law does not do
The measure does not create a retail ibogaine market. It does not establish general medical access, a state-level prescription pathway, or a blanket permission for Colorado residents to obtain ibogaine. Questions about where treatment may be offered elsewhere belong to a different practical inquiry, such as ibogaine treatment locations, and should not be read as a statement of Colorado pilot eligibility.
It also does not alter federal law. Ibogaine remains listed as a Schedule I controlled substance under federal law; the DEA’s drug scheduling overview describes the federal scheduling system that continues to apply. State authorization cannot substitute for applicable federal controls, permissions, or research oversight.
Keep the distinction sharp: a state pilot can organize state licensing and support federal coordination. It cannot independently remove a federal Schedule I classification.
That distinction matters when people compare programs across borders or markets. References to Canadian ibogaine treatment centers, the cost of treatment in Mexico, or ibogaine treatment in Florida describe separate settings, not rights created by HB 26-1325.
03 / PAPER TRAIL
Key dates and the implementation sequence
- Bill passage. HB 26-1325 moves through the Colorado legislative process and is passed by the General Assembly.
- Governor’s signature. The enacted measure becomes the statutory basis for the Ibogaine Research Pilot Program.
- Effective date. The program framework takes effect on the date specified in the enacted law, beginning the state-side implementation period.
The official legislative record is the reliable place to verify enactment details and statutory dates. State announcements should likewise be read as implementation updates, not as evidence of broad access. For a description of how Sagebreak handles those distinctions, see our independence and source approach.
04 / TWO SYSTEMS
Colorado can build a lane; federal rules still control the gate
Federal role
FDA and DEA requirements remain material. Research involving a Schedule I substance operates within federal law; Colorado’s statute does not replace those requirements.
Outstanding hurdle
A state license is not, by itself, an authorization to possess, administer, prescribe, manufacture, or study a federally controlled substance outside applicable federal pathways.
What to watch
Implementation depends on the state program’s rules and licensing activity, alongside the federal permissions and regulatory steps needed for the specific research work at issue.
05 / QUICK CHECK
Questions the pilot does—and does not—answer
Does the pilot mean ibogaine is now generally legal in Colorado?
No. The law establishes a limited research pilot. It does not create retail availability, general medical access, or a state prescription pathway. The federal status remains relevant; ibogaine’s general reference entry can help distinguish the compound from the specific Colorado policy framework.
Does a licensed pilot site mean federal approval is already settled?
No. The state and federal pieces are distinct. A state-side program can support an organized path, but it does not erase the federal regulatory hurdles associated with Schedule I research. This is why general guides about how ibogaine works should not be treated as legal guidance or proof of authorized access.
What should families and advocates avoid assuming?
Avoid treating the bill as an announcement of open treatment availability. Questions such as where ibogaine treatment may be pursued or claimed ibogaine therapy benefits are separate from the legal boundaries of Colorado’s pilot and require careful attention to health, safety, and jurisdiction.
Colorado’s new framework is a defined research-policy experiment: limited in site count, conditioned by state safeguards, and still bounded by federal law.